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ABSTRACT: This study evaluated the renal function of rats subjected to treatment with meloxicam 
(ME) and flunixin meglumine (FM).  Sixty six Wistar rats were divided into three groups (n=22). The 
control group received physiological solution, while the groups treated with ME and MF received two 
subcutaneous doses of 2 and 1.1 mg/kg of the medication, respectively. All animals were subjected to 
the collection 2 ml of blood at the beginning and end of the study to further detect the levels of urea 
and creatinine. Double-factor ANOVA test was applied on these data using a significance level ≤ 
0.05. The conclusion was that the use of both drugs in therapeutic doses caused significant increase 
in the plasma urea level. The values of the plasma creatinine were considered equivalent between 
the groups in all periods. 
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RESUMO: Avaliou-se a função renal de ratos Wistar submetidos ao tratamento com meloxicam (ME) 
e flunixin meglumine (FM). Foram utilizados 66 ratos Wistar distribuídos em três grupos (n=22). O 
grupo controle recebeu solução fisiológica, enquanto os grupos tratados com ME e FM receberam 
duas doses de 2 e 1,1 mg/Kg, respectivamente, da medicação por via subcutânea. Todos os animais 
foram submetidos à coleta de 2 mL de sangue no início e ao fim do estudo para posterior detecção 
dos níveis de uréia e creatinina plasmáticas. A partir destes dados foi feita a aplicação do teste 
ANOVA-fator duplo. O nível de significância utilizado foi ≤0,05. Conclui-se que o uso de ambos os 
medicamentos nas dosagens terapêuticas causou aumento significativo na concentração de uréia 
plasmática, porém a creatinina plasmática permaneceu equivalente em todos os grupos durante o 
período de estudo. 
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INTRODUCTION 
 
 The control of pain in laboratory 
animals is an ethical and legal 
responsibility of researchers and has 
become a growing concern in view of 
the importance of animal welfare for the 
maintenance of their physiological, 
psychological and behavioral conditions 
(Liles & Flecknell, 1992), also minimizes 
animal suffering and distress (ILAR, 
2011). The drugs used for this purpose 
are formulated for use in humans, pets 
or farm animals and, therefore, the 
doses used in laboratory animals are 
usually often extrapolations (King & 
Miller, 1997).  
Various analgesic drugs are 
available for use in laboratory animals 
and can be classified into three groups: 
i. agents acting on the central nervous 
system, ii. substances that block the 
impulses in nociceptors and, iii. agents 
that inhibit the production of chemical 
mediators of inflammation. The last 
group is represented by nonsteroidal 
anti-inflammatory drugs (NSAIDs) 
providing analgesia sufficient to relieve 
postoperative pain without the side 
effects of opioids (Liles & Flecknell, 
1992). 
There are over 50 different NSAIDs 
on the market that share therapeutic 
activities and side effects. The 
mechanism of action of NSAIDs is 
related to inhibition of the enzyme 
cyclooxygenase (COX) that acts in the 
production of prostaglandins, 
prostacyclins and thromboxanes from 
arachidonic acid or linoleic acid  (Ruiz et 
al., 2002; Hinz et al., 2006).  Flunixin 
meglumine (FM) is an NSAID that was 
introduced in veterinary medicine in the 
late 1970s as an effective alternative for 
the treatment of musculoskeletal and 
colic in horses (Macallister et al., 1993). 
Meloxicam (ME) is a NSAID known for 
its potent anti-inflammatory and 
analgesic being used in both humans 
and non humans (Hueza, 2008).   
In humans, the use of NSAIDs in 
hospitalized patients is a cause of acute 
renal failure (ARF) and there is a 
consensus about risks and side effects 
on the kidneys when prescribing these 
drugs in patients with kidney damage 
(Costa et al., 2003). 
Given the growing concern for the 
welfare of laboratory animals and, 
consequently, to control the pain caused 
by surgical procedures performed in 
rats, the search for anti-inflammatory 
insurance to their metabolism has 
increased. Because of this, the present 
study was carried out to evaluate the 
safety of FM and ME for renal 
physiology of rats. 
 
MATERIAL AND METHODS 
 
Sixty six healthy, adult female 
Wistar rats weighing 274 g (± 31 g), 
aged 4-5 months were used in this 
study. The animals had free access to a 
standard commercial diet, water and 
were kept in rooms maintained at 25°C). 
At the beginning of the 
experiment the animals were sedated 
with isoflurane  and submitted to blood 
collection by intracardiac puncture.  The 
animals were divided randomly in three 
different groups; each group consisted 
of twenty-two rats.  Control group (CG) 
was treated with subcutaneous injection 
with physiological solution (2 mL/kg), 
while groups ME and FM were injected 
subcutaneously with meloxicam (2  
mg/kg) (Teixeira, 2010), and flunixin 
meglumine (1,1 mg/Kg) (Hawk, 2005), 
respectively. After 24 hours, a new 
subcutaneous administration of 
physiological solution, meloxicam and 
flunixin meglumine was performed. 
Seven days after the second 
administration was collected new blood 
sample. The material was stored in 
tubes with anticoagulant (EDTA) and 
centrifuged at 1000 g for 12 minutes for 
extraction of plasma and subsequent 
detection of levels of urea and 
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creatinine. For the quantification of urea 
and creatinine in mg/dL, enzymatic 
colorimetric tests were used. 
The results were submitted to the 
Lilliefors test. Once the data was 
presented in normal distribution, Two-
way ANOVA test was used to test the 
null hypothesis of equal means of urea 
and creatinine in GC, ME and FM at the 
initial and final analysis period. In 
situations of statistical significance, the 
Least Square Difference (LSD) test was 
used for comparison between groups. A 
significance level ≤ 0.05 was used in all 
tests. 
 
RESULTS 
 
The analysis of urea values 
showed statistically significant 
differences (P<0.05) between groups in 
the final period of experimentation (F2, 
126=6.9628; P=0.00135). It was found 
that the mean values of urea were 
considered equivalent between the 
groups in the early period of 
experimentation, indicating that the three 
groups were equivalent with regard to 
renal physiology (Fig. 1). However, in 
the final period of experimentation, FM 
and ME groups had a significantly higher 
mean than the CG (P=0.0000, 
P=0.0005, respectively), but equivalent 
to each other (P=0.063) (Fig. 1, Table 
1). 
The analysis of creatinine values 
showed no statistically differences 
(P>0.05) between groups in the final 
period of experimentation (F2, 
126=0.04672; P=0.95437). It was found 
that the mean values of creatinine were 
considered equivalent between the 
groups in all periods of experimentation 
(Table 1). 
 
 
 
 
 
DISCUSSION 
 
Analgesics are often administered 
to laboratory animals without proper 
assessment of its efficacy and safety. 
NSAIDs are a group of anti-inflammatory 
drugs with great potential to act as 
painkillers when opioids are 
contraindicated. However, the doses 
indicated for other species may result in 
inadequate analgesia or serious side 
effects since there is little information on 
the effects of these compounds on the 
metabolism of laboratory animals (Liles 
& Flecknell, 1992; King & Miller, 1997).  
In this study we used the doses 
recommended in the literature aiming to 
obtain results that could indicate the 
effect of therapeutic doses on renal 
function in Wistar rats. The dose of 
flunixin meglumine indicated by Hawk et 
al. (2005) varies from 1.1 to 2.5mg/kg 
while the dose of meloxicam cited by 
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Viana (2007) is 2 mg/kg for mice. The 
literature does not describe the specific 
dose for rats, since the use of 
analgesics for rodents in routine 
laboratories is recent and has become 
an ethical requirement to conduct 
studies (Hawk et al., 2005). 
NSAIDs may interfere with the 
autoregulation of renal blood flow and 
precipitate renal hypoperfusion, and 
should be used with caution in patients 
with mild hypovolemia and hypotension 
(Teixeira, 2010). Other adverse effects 
include inhibition of the biosynthesis of 
prostaglandin E2 and I2 involved in the 
maintenance of blood and renal 
vasodilatation compensating change 
that occurs in response to the action of 
norepinephrine and angiotensin II (Hinz 
et al., 2006).  Angiotensin II is primarily 
responsible for the maintenance of renal 
perfusion and glomerular filtration 
because it causes increased resistance 
of the efferent glomerular arteriole and 
stimulation of intrarenal vasodilating 
prostaglandins (Mindell & Chertow, 
1997). 
Prostaglandins and 
thromboxanes are also mediators of the 
inflammatory response and participate in 
pathophysiological processes in multiple 
organs and systems, thus interrupting its 
production by NSAIDs may impair renal 
blood flow leading to increased ischemic 
lesions (Hilário et al., 2006; Hinz et al., 
2006; Chahade et al., 2008) and 
nephrotoxicity (Ruiz, 2002). Especially in 
the urinary system, prostaglandins PGE 
2 and PGI 2 infused directly into the 
renal arteries increase renal plasma flow 
and hence the rate of glomerular 
filtration rate (Wannmacher & Ferreira, 
2006). 
There are three forms of the 
enzyme cyclooxygenase, COX-1, COX-
2 and COX-3 (Chahade et al., 2008). 
COX-1 is a constitutional enzyme and is 
involved in the homeostasis of many 
tissues. COX-2 is an enzyme that 
produces inflammatory mediators of 
inflammation when induced by activated 
inflammatory cells (Hinz et al., 2006). A 
variant of the gene for COX-1 is newly 
discovered, called COX-3. Its specific 
function remains unknown (Miller et al., 
1978; Hinz et al., 2006). All three 
isoforms are selectively inhibited by 
NSAIDs (Chahade et al., 2008). 
NSAIDs used in this study were 
meloxicam and flunixin meglumine and 
both can be used to promote analgesia 
in experimental animals. The side 
effects attributed to the use of 
meloxicam are decrease in renal blood 
flow, gastrointestinal ulceration and 
inhibition of platelet aggregation 
(Teixeira, 2010). It was the first anti-
inflammatory marketed medication 
developed from a molecule inhibitor of 
COX-2, maintaining a partial blocking of 
COX-1 (Chahade et al., 2008). The 
preferential inhibition of prostaglandin-
related COX-2 assigned to this drug 
reduces the occurrence of 
gastrointestinal side effects compared to 
the inhibition produced by less specific 
NSAIDs (Cooper et al., 2009) although it 
retains some activity against COX-1 
(Furst, 1997; Suckow et al., 2006). But 
the selective COX 2 has shown 
nephrotoxic effects compared with 
nonselective (Perazella & Tray, 2001). 
The flunixin meglumine is a 
potent COX inhibitor with analgesic and 
antipyretic action. It is considered a 
good analgesic for acute pain control 
and postoperative been widely used in 
the treatment of infectious diseases, 
inflammation, fever, pain, visceral and 
skeletal muscle in cattle, pigs, horses 
and dogs (Taylor et al., 1994; Pulz et al., 
2005; Ávila, 2010). However, there is no 
clinical experience in laboratory animals 
comparable to that achieved in pets and 
farm animals. Side effects commonly 
attributed to the use of FM are ulcerative 
character throughout the alimentary 
canal. These effects are caused by COX 
inhibition and, consequently, by the 
reduced production of prostaglandins 
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(Hinz et al., 2006; Wannmacher & 
Ferreira, 2006; Chahade et al., 2008). 
According to the results obtained 
in this study, it was observed that the 
use of 1.1 mg/kg flunixin meglumine and 
2 mg/kg meloxicam, caused a significant 
increase in plasma urea level in the 
treated animals compared to the control 
group, however creatinine values 
showed no statistically differences 
(P>0.05) between groups in the final 
period of experimentation.  
 The hyperuremia is one of the 
main laboratory findings in patients with 
renal insufficiency and is directly related 
to the deficiency in nitrogen excretion by 
the kidneys (Schossler et al., 2001). The 
increase in plasma urea can be used as 
an indicator of renal function, since 
approximately 40% of urea is 
reabsorbed by the renal tubules (Alencar 
et al., 2002). 
As the creatinine excretion occurs 
by kidneys, this metabolite is considered 
the gold standard for measuring renal 
function. The increase in serum 
creatinine may indicate impairment 
kidney function (Bush, 2004). In this 
study, the mean values of creatinine 
were considered equivalent between the 
groups in all periods of experimentation. 
In pre-renal ARF, when the causative 
agent is the use of NSAIDs, the 
clearance of urea falls rapidly in relation 
to creatinine clearance because there is 
retrograde spread of the filtered urea 
and not creatinine (Chertow et al., 1995) 
and increases proportionally to the 
decrease of functional nephrons (Guyton 
& Hall, 2011). In this case the urea, not 
creatinine, may be a reliable parameter 
for diagnosis of ARF. 
The use of flunixin meglumine 
and meloxicam in the conditions 
described in this study caused changes 
in plasma urea concentration of the 
treated mice when compared with the 
control group. At the beginning of the 
study, the mean values of urea were 
similar in all groups, demonstrating 
equivalence of renal function in the 
animals. Nevertheless, at the end of the 
experimental period the animals that 
received flunixin and meloxicam showed 
means significantly higher than the 
control group (P=0.0000, P=0.0005, 
respectively), but equivalent to each 
other (P=0.063). Given that urea may 
increase with dehydration, the water 
consumption of each animal was 
measured and showed no significant 
changes (data not shown). 
Rats, especially females 
(Giesbrecht & Zyngier, 1979), have 
shown greater susceptibility to the 
effects of NSAIDs than the mouse and 
guinea pig (King & Miller, 1997) and it 
can be assumed that the route of 
administration is a relevant factor for the 
effect of the drug on renal physiology. In 
the study by Barbosa et al. (2010) no 
changes were observed in the kidneys 
of rats given dosages of meloxicam 2 
and 10 mg / kg intragastrically which 
may suggest that there was a 
considerable loss of the drug in its first 
passage through the liver before being 
absorbed into the systemic circulation. 
The most common route of 
administration is oral, but involves the 
longer path and complicated for access 
tissues since the first pass metabolism 
in the intestine or liver limits the 
effectiveness of many drugs taken by 
this route (Mycek et al., 1998). 
Furthermore, it should resist the 
digestive acids across the 
gastrointestinal mucosa before being 
absorbed into the circulatory system. 
The oral route allows the active drug to 
be absorbed more gradually minimizing 
the adverse effects. The subcutaneous 
route allows more rapid absorption and it 
is proportional to blood flow. The drug 
administered by this route passes 
through the capillary endothelium and 
reaches the bloodstream, ensuring a 
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higher absorption (Giesbrecht & Zyngier, 
1979). 
According Wannmacher and 
Ferreira (2006), the absorption of a drug 
influences the beginning and intensity of 
the pharmacological effect. The 
evaluation of the pharmacokinetic profile 
of meloxicam in different species 
showed that in rats, meloxicam is 
concentrated primarily in the kidneys 
and liver similar to what occurs in 
humans (Engelhardt, 1996; Busch et al., 
1998). In dogs, meloxicam has a broad 
range of security even when there is 
prolonged use, however, like other 
NSAIDs, can cause gastrointestinal 
toxicity (Fish et al., 2008). 
In the literature, numerous 
experiments are found that evaluate the 
efficacy of flunixin meglumine in large 
animals including oral ulcers, gastric and 
duodenal necrosis, renal and 
hematological diseases (Macallister et 
al., 1993; Welsh & Nolan, 1995; Beretta 
et al., 2005). Pulz et al. (2002) 
suggested that flunixin is capable of 
causing renal ischemia in dogs due to 
drug interactions with other anesthetics, 
but there are few studies that evaluate 
possible adverse effects caused by it in 
other animals, especially in laboratory 
animals. 
Elmas et al. (2008) evaluated the 
pharmacokinetics of flunixin meglumine 
in healthy and endotoxemic rabbits and 
observed that this drug can be co-
administered for the treatment of 
endotoxemia in these animals. Liles and 
Flecknell (1992), Arumugam et al. 
(2003), Martin and Stewart (2003) 
believe that this drug may be an 
alternative for the treatment of pain in 
rodent species. However, Taylor et al. 
(1994) suggest that differences in half-
life of NSAIDs among species may be 
an impediment to the extrapolation of 
results obtained in different species. 
Therefore, the use of NSAIDs in 
laboratory animals should not be done 
under any circumstances. One should 
take into account their effectiveness in 
specific clinical situations and adjust the 
dose in a treatment regimen pre-
established (Liles & Flecknell, 1992).  
 
CONCLUSION 
 
The results of this study suggest 
that the use of meloxicam and flunixin 
meglumine at doses recommended in 
the literature to laboratory mice, 
specifically, caused increase in the 
plasma urea level, but the values of the 
plasma creatinine were considered 
equivalent between the groups in all 
periods.   
If necessary, the use of these 
drugs should be done with caution 
because further studies in Wistar rats 
are needed in order to evaluate the 
dosage of these drugs in 
experimentation animals. 
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